{"groups":[{"description":"Osimertinib (AZD9291) 80 mg once daily (QD) with Carboplatin (AUC of 5 mg/mL/min \\[AUC5\\]) and Pemetrexed (500 mg/m2), both administered every 3 weeks (Q3W) for 4 cycles, followed by Osimertinib 80 mg once daily plus Pemetrexed maintenance (500 mg/m2) Q3W","id":"FG000","title":"Safety Run-In: AZD9291 + Carboplatin + Pemetrexed"},{"description":"Osimertinib (AZD9291) 80 mg once daily (QD) with Cisplatin (75 mg/m2) and Pemetrexed (500 mg/m2), both administered every 3 weeks (Q3W) for 4 cycles, followed by Osimertinib 80 mg once daily plus Pemetrexed maintenance (500 mg/m2) Q3W","id":"FG001","title":"Safety Run-In: AZD9291 + Cisplatin + Pemetrexed"},{"description":"Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W","id":"FG002","title":"Randomized: AZD9291 + Chemo"},{"description":"Osimertinib (AZD9291) 80mg QD.","id":"FG003","title":"Randomized: AZD9291"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"197"},{"groupId":"FG003","numSubjects":"191"}],"type":"Ongoing Study at Data Cut Off (03APR2023)"},{"reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"70"},{"groupId":"FG003","numSubjects":"77"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"}],"type":"Screen Failure"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"11"},{"groupId":"FG003","numSubjects":"9"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"279"},{"groupId":"FG003","numSubjects":"278"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"212"},{"comment":"Participants in this treatment did not receive Carboplatin/Cisplatin treatment.","groupId":"FG003","numSubjects":"0"}],"comment":"At Time of Data Cut Off (03APR2023)","type":"Completed 4 Cycles of Carboplatin/Cisplatin Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"154"},{"groupId":"FG003","numSubjects":"123"}],"comment":"At time of Data Cut Off (03APR2023)","type":"Ongoing Any Study Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"276"},{"groupId":"FG003","numSubjects":"275"}],"comment":"Includes Osimertinib, Cisplatin, Carboplatin, or Pemetrexed","type":"Received at Least One Dose of Investigational Product"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}],"comment":"At time of Data Cut Off (03APR2023)","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"14"},{"groupId":"FG002","numSubjects":"279"},{"groupId":"FG003","numSubjects":"278"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"A total of 587 participants were enrolled in the study, 30 in the SRI and 557 in the Randomization component of the study. 6 participants were randomized to the Randomization component but did not receive any study treatment (2 Screen Failures, 2 Subject Decision, and 2 Deaths)."}